Literature DB >> 10797498

Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients.

Y Miyoshi1, H Uemura, K Fujinami, K Mikata, M Harada, H Kitamura, Y Koizumi, Y Kubota.   

Abstract

BACKGROUND: Oncogene amplification and chromosomal anomalies are found in many solid tumors and are often associated with aggressiveness of cancer. We evaluated the frequency and the association of c-myc and androgen receptor (AR) gene amplification and gain of chromosome 8 or X in prostate cancer in Japanese patients.
METHODS: We examined a total of 42 prostate cancer specimens, using fluorescence in situ hybridization (FISH). Dual-labeling hybridization with a directly labeled centromere probe for chromosome 8 or X together with a probe for the c-myc or AR locus was performed.
RESULTS: Gain of chromosome 8 was identified in 54.8% of specimens and was associated with Gleason sum and nuclear anaplasia in untreated prostate cancers. c-myc gene amplification was found in 14.3% of specimens. Gain of chromosome X was identified in 42.9% of specimens. AR gene amplification was detected in 0 of 37 untreated prostate cancers, but in 1 of 5 hormone-refractory prostate cancers.
CONCLUSIONS: Our results suggest that c-myc and AR gene amplification and gain of chromosome 8 or X may be associated with the development and progression of prostate cancers. These results obtained in Japanese cases are consistent with the results observed in prostate cancer in Western countries. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10797498     DOI: 10.1002/(sici)1097-0045(20000515)43:3<225::aid-pros9>3.0.co;2-7

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  19 in total

1.  Identification of a high frequency of chromosomal rearrangements in the centromeric regions of prostate cancer patients.

Authors:  V Balachandar; B Lakshman Kumar; K Sasikala; P Manikantan; R Sangeetha; S Mohana Devi
Journal:  J Zhejiang Univ Sci B       Date:  2007-09       Impact factor: 3.066

2.  Androgen receptor coregulators NOCR1, TIF2, and ARA70 may account for the hydroxyflutamide insensitivity of prostate cancer cells.

Authors:  Y Wang; J-Q Li; C Shao; C-H Shi; F Liu; Z-Y Yang; J-X Qiu; Y-M Li; Q Fu; W Zhang; W Xue; Y-H Lei; J-Y Gao; J-Y Wang; X-P Gao; J-L Yuan; T-Y Bao; Y-T Zhang
Journal:  Ir J Med Sci       Date:  2011-07-05       Impact factor: 1.568

Review 3.  The convergence of hormone regulation and cell cycle in prostate physiology and prostate tumorigenesis.

Authors:  Joanne N Davis; Mark L Day
Journal:  Mol Biotechnol       Date:  2002-10       Impact factor: 2.695

Review 4.  Translational and clinical implications of the genetic landscape of prostate cancer.

Authors:  Daniel E Spratt; Zachary S Zumsteg; Felix Y Feng; Scott A Tomlins
Journal:  Nat Rev Clin Oncol       Date:  2016-06-01       Impact factor: 66.675

5.  Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription.

Authors:  Liang-Nian Song; Roger Herrell; Stephen Byers; Salimuddin Shah; Elizabeth M Wilson; Edward P Gelmann
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

6.  Transcription factor KLLN inhibits tumor growth by AR suppression, induces apoptosis by TP53/TP73 stimulation in prostate carcinomas, and correlates with cellular differentiation.

Authors:  Yu Wang; Deepa Radhakrishnan; Xin He; Donna M Peehl; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2013-02-05       Impact factor: 5.958

7.  Myc confers androgen-independent prostate cancer cell growth.

Authors:  David Bernard; Albin Pourtier-Manzanedo; Jesús Gil; David H Beach
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

8.  Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations.

Authors:  Jin-Rong Zhou; Lunyin Yu; Luiz F Zerbini; Towia A Libermann; George L Blackburn
Journal:  Int J Cancer       Date:  2004-07-20       Impact factor: 7.396

Review 9.  The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.

Authors:  Michael V Fiandalo; Wenjie Wu; James L Mohler
Journal:  Curr Drug Targets       Date:  2013-04       Impact factor: 3.465

10.  Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.

Authors:  Wennuan Liu; Sari Laitinen; Sofia Khan; Mauno Vihinen; Jeanne Kowalski; Guoqiang Yu; Li Chen; Charles M Ewing; Mario A Eisenberger; Michael A Carducci; William G Nelson; Srinivasan Yegnasubramanian; Jun Luo; Yue Wang; Jianfeng Xu; William B Isaacs; Tapio Visakorpi; G Steven Bova
Journal:  Nat Med       Date:  2009-04-12       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.